Standard BioTools Inc. (LAB)

The past six months have seen several significant events impacting Standard BioTools, Inc.'s stock price. Standard BioTools completed the sale of its SomaLogic business to Illumina for up to $425 million in cash. Shareholders had experienced a 76% loss from investing in the stock over the past five years. The company announced preliminary fourth-quarter and full-year 2025 revenue, which exceeded prior guidance. Institutional owners were reportedly considering "drastic measures" following a US$96 million drop in the company's market capitalization. Casdin funds made multiple purchases of Standard BioTools shares. Standard BioTools announced a collaboration with Molecular Instruments. The company reported its third-quarter 2025 financial results, where EPS missed forecasts and revenue was down year-over-year.

Specific information regarding the demand seasonality for Standard BioTools, Inc.'s products and services is not explicitly detailed. Demand for instruments has been noted to be impacted by capital constrained end-markets globally. The expectation of strong, recurring revenue growth from diverse global research and clinical markets implies a generally growing market rather than significant seasonal fluctuations.

Standard BioTools, Inc. is a prominent player in the healthcare sector, specializing in advanced instrumentation and consumables for biomedical research. The company, formerly Fluidigm Corporation, focuses on proteomics and genomics, offering products like the SomaScan platform, CyTOF technology platform, Hyperion spatial biology platform, and Biomark X9 system. It sells its products to academic research institutions, cancer centers, clinical research laboratories, and biopharmaceutical, biotechnology, and plant and animal research companies.

Standard BioTools, Inc. has a global presence, selling its products and services across the Americas, Europe, the Middle East, Africa, and the Asia Pacific regions. The company also maintains a global support team.

Standard BioTools' brand reputation has been influenced by strategic developments and financial challenges. Strategic partnerships and licensing agreements bolster its credibility. The successful integration of SomaLogic and an improved on-time delivery rate have enhanced customer satisfaction. However, the company has faced profitability challenges, with deepening net losses and negative revenue growth. The recent sale of SomaLogic to Illumina represents a divestment of a key business segment.

Standard BioTools Inc. has 248 institutional owners and shareholders holding a total of 309,940,178 shares. Major institutional owners include Casdin Capital, LLC, Viking Global Investors Lp, BlackRock, Inc., Vanguard Group Inc, Mak Capital One Llc, Long Focus Capital Management, Llc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Geode Capital Management, Llc, IWM - iShares Russell 2000 ETF, and State Street Corp. Insiders hold 23.16% of the company's stock. A significant ownership shift occurred in December 2022 when Casdin Capital and Viking Global led a $250 million recapitalization.